Which hedge funds own ELVN? ENLIVEN THERAPEUTICS INC, Q2 2026 13F holders
65 tracked hedge funds disclosed a position in ELVN (ENLIVEN THERAPEUTICS INC) in their Q2 2026 13F filings, worth $2.0bn in total. The largest holder by portfolio weight is Commodore Capital LP at 9.9% of its book. 28 opened a new position this quarter: Tri Locum Partners LP, Squadron Capital Management LLC, Silverarc Capital Management, LLC, Ishara Investments LP. 10 exited: Capricorn Fund Managers Ltd, Caption Management, LLC, Scientech Research LLC.
- 65
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 28
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 10
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $267m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $38.3m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $2.0bn
- Combined value Sum of the holders' reported positions in the security.
- 5.2%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Capricorn Fund Managers Ltd | 2.3% | $14.5m |
| Caption Management, LLC | 0.7% | $14.5m |
| Scientech Research LLC | 0.5% | $620k |
| Prelude Capital Management, LLC | 0.2% | $2.1m |
| SummitTX Capital, L.P. | 0.09% | $2.7m |
| FORA Capital, LLC | 0.04% | $577k |
| Quantbot Technologies LP | 0.02% | $420k |
| ExodusPoint Capital Management, LP | 0.01% | $1.2m |
| Entropy Technologies, LP | 0.01% | $239k |
| Walleye Capital LLC | 0.01% | $1.5m |
Ownership over time
Who discovered ELVN first? Beta
| Commodore Capital LP high conviction | Q1 2023 | +8.0 pts |
| Fairmount Funds Management LLC high conviction | Q1 2023 | +6.5 pts |
| Orbimed Advisors LLC high conviction | Q1 2023 | +4.8 pts |
| Venrock Adviser, LLC high conviction | Q1 2023 | +1.9 pts |
| Logos Global Management LP | Q1 2024 | +1.3 pts |
| BML Capital Management, LLC | Q1 2023 | −0.6 pts |
| Cormorant Asset Management, LP | Q1 2023 | −1.0 pts |
| 5AM Venture Management, LLC high conviction | Q1 2023 | −3.6 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.